Barclays Issues Pessimistic Forecast for TScan Therapeutics (NASDAQ:TCRX) Stock Price
TScan Therapeutics (NASDAQ:TCRX – Free Report) had its price objective trimmed by Barclays from $14.00 to $3.00 in a report published on Friday,Benzinga reports. The firm currently has an overweight rating on the stock. A number of other equities research analysts also recently weighed in on the stock. Wedbush restated an “outperform” rating and issued […]
TScan Therapeutics (NASDAQ:TCRX – Free Report) had its price objective trimmed by Barclays from $14.00 to $3.00 in a report published on Friday,Benzinga reports. The firm currently has an overweight rating on the stock. A number of other equities research analysts also recently weighed in on the stock. Wedbush restated an “outperform” rating and issued […]
